The HLA-B44 model was generated by Pharmexa-Epimmune. The model was created by microinjecting a chimeric transgene combining a fragment of the genomic clone of the human HLA-B*4002 gene that included leader sequence, α1 and α2 domains ligated to a fragment of the murine H2-Kb gene containing the α3, transmembrane and cytoplasmic domains, all under the control of the murine H2-Kb promoter. This transgene was microinjected into C57BL/6 zygotes. The resultant mice from Founder Line B44.01 were on an inbred C57BL/6 background. The line was maintained by breeding hemizygotes to wild type C57BL/6NTac mice for 4 generations. Taconic received stock from Pharmexa-Epimmune in 2008. The line was embryo transfer derived by breeding C57BL/6NTac wild type females to hemizygous males and then was intracrossed to homozygosity. The colony is maintained through breeding of homozygous males to homozygous females. In the production colony, wild type BALB/cAnNTac females are bred to homozygous males on the C57BL/6NTac background to produce CB6F1 pups.
Depla E, Van der Aa A, Livingston BD, Crimi C, Allosery K, De Brabandere V, Krakover J, Murthy S, Huang M, Power S, Babé L, Dahlberg C, McKinney D, Sette A, Southwood S, Philip R, Newman MJ, Meheus L. (2008) Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections. J Virol 82(1):435-50.
This publication does not describe the HLA-B44 strain, but the HLA-B44 strain was generated in a similar manner to that of the other transgenic HLA mouse strains described in the publication and may be used for similar types of experiments.